A single centre pilot experience with 18F-JK-PSMA-7 PET-CT in the staging of prostate cancer

A single centre pilot experience with 18F-JK-PSMA-7 PET-CT in the staging of prostate cancer

Background: The sensitivity and specificity of bone scintigraphy and thoraco-abdominopelvic CT scans traditionally used for the staging of prostate cancer don’t meet clinical requirements. In 2020 18F-JK-PSMA-7 positron emission tomography-computed tomography (PET-CT) became available in our coun...

Full description

Bibliographic Details
Main Authors:	Szigeti András, Kocsis Károly, Ambrus Adél, Kránitz Noémi, Szepesváry Zsolt, Kullmann Tamás
Format:	Article
Language:	English
Published:	MRE Press 2022-02-01
Series:	Journal of Men's Health
Subjects:	prostate cancer psma pet-ct biochemical relapse therapy optimisation
Online Access:	https://imrpress.com/journal/JOMH/18/2/10.31083/jomh.2021.133

Similar Items

Clinical experience with 18F-JK-PSMA-7 when using a digital PET/CT
by: Irina Vierasu, et al.
Published: (2022-03-01)

68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer
by: Amir Iravani, et al.
Published: (2017-12-01)

Histologically Confirmed Testicular Metastasis Revealed by [<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Negative Conventional PSMA PET/CT Imaging
by: Florian Rosar, et al.
Published: (2023-04-01)

Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer
by: Melanie Hohberg, et al.
Published: (2019-07-01)

Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy
by: Nina-Sophie Schmidt-Hegemann, et al.
Published: (2018-03-01)

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
by: Alexander D. Combes, et al.
Published: (2022-10-01)

Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy
by: Sara Harsini, et al.
Published: (2023-03-01)

<sup>68</sup>Ga-PSMA PET/CT in Recurrent Prostate Cancer after Radical Prostatectomy Using PSMA-RADS Version 2.0
by: Gabriele Masselli, et al.
Published: (2024-06-01)

Prostate Cancer Biochemical Recurrence Resulted Negative on [<sup>68</sup>Ga]Ga-PSMA-11 but Positive on [<sup>18</sup>F]Fluoromethylcholine PET/CT
by: Riccardo Laudicella, et al.
Published: (2022-09-01)

Differences in Distribution and Detection Rate of the [<sup>68</sup>Ga]Ga-PSMA Ligands PSMA-617, -I&T and -11—Inter-Individual Comparison in Patients with Biochemical Relapse of Prostate Cancer
by: Falk Gühne, et al.
Published: (2021-12-01)

A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa
by: Nina-Sophie Schmidt-Hegemann, et al.
Published: (2021-10-01)

Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer
by: Sara Harsini, et al.
Published: (2024-08-01)

cfDNA fragmentation patterns correlate with tumor burden measured via PSMA PET/CT volumetric parameters in patients with biochemical recurrence of prostate cancer
by: Gary Amseian, et al.
Published: (2024-12-01)

Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System
by: Zsófia Sára Mikó, et al.
Published: (2024-10-01)

[68Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [177Lu]Lu-PSMA therapy in relapsing high-grade glioma
by: Peter Truckenmueller, et al.
Published: (2022-09-01)

Lessons from a 3-Year Review of PSMA PET-CT in a Tertiary Setting: Can We Fine Tune Referral Criteria by Identifying Factors Predicting Positivity and Negativity?
by: Vineet Pant, et al.
Published: (2023-07-01)

Plug inguinal hernia repair mimicking nodal spread of prostate cancer on PSMA-PET/CT
by: Genevieve C. Muñoz, MA, et al.
Published: (2023-01-01)

PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression
by: Florian Rosar, et al.
Published: (2022-05-01)

Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis
by: Andrei Gafita, et al.
Published: (2019-12-01)

[18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine
by: Cato C. Loeff, et al.
Published: (2024-11-01)

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET
by: Kevin H. Leung, et al.
Published: (2022-12-01)

COMPARISON OF 68GA-PSMA AND 18F-FDG-PET/CT IN THE ASSESSMENT OF DESMOID TUMORS
by: Tobias Luis dos Reis, et al.
Published: (2024-04-01)

Diagnostic Role of <sup>18</sup>F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review
by: Salam Awenat, et al.
Published: (2021-03-01)

PSMA-Positive Low Malignant Gastrointestinal Stromal Tumor in the Stomach on F-18-PSMA-1007 PET/CT
by: Peter Iversen, et al.
Published: (2022-01-01)

Parathyroid Adenoma Detected in <sup>68</sup>Ga-PSMA PET/CT but Not in the Dedicated Imaging Modalities
by: Maja Cieślewicz, et al.
Published: (2024-08-01)

PSMA-PET/CT in Patients with Recurrent Clear Cell Renal Cell Carcinoma: Histopathological Correlations of Imaging Findings
by: Falk Gühne, et al.
Published: (2021-06-01)

Expanding the role of PSMA PET in active surveillance
by: Anika Jain, et al.
Published: (2023-04-01)

Optimisation of second line antihormonal treatment for castration resistant metastatic prostate cancer
by: Kullmann Tamás, et al.
Published: (2022-04-01)

Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET/CT with an inter- and intrapatient based analysis
by: Cristina E. Popescu, et al.
Published: (2024-04-01)

18F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study
by: Irina Vierasu, et al.
Published: (2023-01-01)

Early treatment response assessment with [177Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET
by: David Ventura, et al.
Published: (2024-09-01)

COMPARISON OF PET/CT IMAGES WITH 18F-FDG AND 18F-PSMA-1007 IN MUSCULOSKELETAL TUMORS TO EVALUATE THE POTENTIAL OF THERANOSTICS APPROACH
by: Mayara Branco E. Silva, et al.
Published: (2024-04-01)

68Ga-PSMA and 11C-Choline comparison using a tri-modality PET/CT-MRI (3.0 T) system with a dedicated shuttle
by: Omar Alonso, et al.
Published: (2018-05-01)

PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions
by: Jennifer le Guevelou, et al.
Published: (2021-08-01)

Ductal prostate cancer staging: Role of PSMA PET/CT
by: Pietro Pepe, et al.
Published: (2024-02-01)

COMPARISON OF 18F-FDG AND 18F-PSMA PET/CT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
by: Najua Abou Arabi Silveira, et al.
Published: (2024-04-01)

Active Lumbar Spondylodiscitis on [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT Mimicking Bone Metastasis
by: Florian Rosar, et al.
Published: (2023-12-01)

Neuroendocrine cancer of the prostate. Two case reports
by: Tamás Kullmann, et al.
Published: (2022-03-01)

Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer
by: Rie von Eyben, et al.
Published: (2023-08-01)

68Ga-PSMA PET/CT in prostate cancer patients – patterns of disease, benign findings and pitfalls
by: Zohar Keidar, et al.
Published: (2018-11-01)